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ABSTRACT
Rationale Idiopathic pulmonary ﬁbrosis (IPF) is the
most rapidly progressive and fatal of all ﬁbrotic
conditions with no curative therapies. Common
pathomechanisms between IPF and cancer are
increasingly recognised, including dysfunctional pan-PI3
kinase (PI3K) signalling as a driver of aberrant
proliferative responses. GSK2126458 is a novel, potent,
PI3K/mammalian target of rapamycin (mTOR) inhibitor
which has recently completed phase I trials in the
oncology setting. Our aim was to establish a scientiﬁc
and dosing framework for PI3K inhibition with this agent
in IPF at a clinically developable dose.
Methods We explored evidence for pathway signalling
in IPF lung tissue and examined the potency of
GSK2126458 in ﬁbroblast functional assays and
precision-cut IPF lung tissue. We further explored the
potential of IPF patient-derived bronchoalveolar lavage
(BAL) cells to serve as pharmacodynamic biosensors to
monitor GSK2126458 target engagement within the
lung.
Results We provide evidence for PI3K pathway
activation in ﬁbrotic foci, the cardinal lesions in IPF.
GSK2126458 inhibited PI3K signalling and functional
responses in IPF-derived lung ﬁbroblasts, inhibiting Akt
phosphorylation in IPF lung tissue and BAL derived cells
with comparable potency. Integration of these data with
GSK2126458 pharmacokinetic data from clinical trials in
cancer enabled modelling of an optimal dosing regimen
for patients with IPF.
Conclusions Our data deﬁne PI3K as a promising
therapeutic target in IPF and provide a scientiﬁc and
dosing framework for progressing GSK2126458 to
clinical testing in this disease setting. A proof-of-
mechanism trial of this agent is currently underway.
Trial registration number NCT01725139, pre-clinical.
INTRODUCTION
Idiopathic pulmonary ﬁbrosis (IPF) represents one
of the most rapidly progressive ﬁbrotic conditions
with a median survival of 3.5 years from diagno-
sis,1 worse than many cancers. The last decade has
seen an exponential rise in clinical trial activity in
IPF with agents which exert pleiotropic effects,
such as pirfenidone (Esbriet) and nintedanib (Ofev)
recently granted approval as the ﬁrst agents to slow
disease progression.2 3 However, there still remains
an urgent need to develop therapeutic strategies
which halt rather than slow disease progression.
Fibrotic foci, the sentinel lesions in IPF, comprise
ﬁbroblasts and α smooth muscle actin positive
(αSMA+) myoﬁbroblasts embedded in a type I
collagen-rich matrix. These lesions are thought to
represent the leading edge of the relentless ﬁbrotic
response and arise as a result of a highly abnormal
wound healing response characterised by dysregu-
lated epithelial/mesenchymal crosstalk and a
complex network of proliferation and differenti-
ation signals received from a remodelled and
homeostatically degenerate microenvironment4–7
(reviewed in4). Parallels between IPF and cancer are
increasingly recognised, with active signalling path-
ways, transcriptomic and miRNA proﬁles and epi-
genetic signatures showing a considerable degree of
overlap with lung cancer.8–11 Moreover, increased
18F-ﬂuorodeoxyglucose (FDG) uptake, a marker of
Key messages
What is the key question?
▸ Is there a scientiﬁc rationale for the use of a
clinically advanced pan-PI3 kinase (PI3K)/
mammalian target of rapamycin (mTOR)
inhibitor in idiopathic pulmonary ﬁbrosis (IPF)?
What is the bottom line?
▸ We provide a comprehensive scientiﬁc and
dosing framework for targeting PI3 kinase
signalling in IPF with the pan-PI3 kinase/mTOR
inhibitor, GSK2126458, based on the
exploration of novel functional endpoints in
patient-derived cells and precision cut lung
slices.
Why read on?
▸ This study provides key data to support the
progression of this agent to a proof-of-
mechanism trial in patients with IPF and further
proposes a roadmap for the repositioning of
existing oncology agents as novel therapeutic
agents in the IPF setting with minimal
requirement for the additional use of
experimental animals.
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aerobic glycolysis in cancer cells, was recently reported in the
lungs of patients with IPF.12 Together these observations
support the notion that a number of pharmacological agents
developed for oncology might be explored as potential thera-
peutic agents in the setting of IPF.
Class 1 PI3K form an important oncogenic signalling node,
integrating signals from a variety of inputs including tyrosine
kinase receptors, G-protein coupled receptors and activated
Ras,13 to mediate a variety of cellular processes, including cell
cycle progression, growth and proliferation, metabolic and syn-
thetic pathways in addition to inﬂammatory responses. There is
evidence that class 1 PI3K isoforms, most notably p110γ,
exhibit increased expression in IPF tissue and ﬁbroblast lines,14
with signalling activated downstream of several key proﬁbrotic
growth factors implicated in IPF, including platelet-derived
growth factor and transforming growth factor (TGF)-β1.
15 16
Evidence suggests that dysregulated PI3K signalling due to low
activity of the tumour suppressor, phosphatase and tensin
homologue (PTEN) may contribute to the proﬁbrotic phenotype
of IPF myoﬁbroblasts,17 18 and moreover that inhibition of class
1 PI3K has anti-ﬁbroproliferative effects in vitro and in tumour
necrosis factor α induced ﬁbrosis in vivo.19 20
GSK2126458 is a potent, highly selective pyridilsulfonamide
inhibitor of class 1 isozymes of PI3K in addition to mammalian
target of rapamycin (mTOR).21 Originally developed in the
oncology setting, GSK2126458 is currently (at the time of
writing) being evaluated in a phase I open-label dose escalation
trial in subjects with refractory solid tumours or lymphoma
(https://clinicaltrials.gov/ct2/show/NCT00972686).
The aim of the present study was to evaluate the scientiﬁc
and dose rationale for re-positioning GSK2126458 as a poten-
tial novel therapeutic agent for IPF. We explore evidence for
PI3K pro-ﬁbrotic signalling in IPF lung tissue in combination
with performing in vitro pharmacological assessment of
GSK2126458 and related development compounds in lung IPF
and non-IPF control ﬁbroblasts. We also assess inhibitor effects
using novel functional endpoints in precision-cut IPF tissue
slices, and further evaluate pAkt levels in IPF bronchoalveolar
(BAL) cells as a potential pharmacodynamic (PD) biomarker to
monitor target engagement in future clinical studies. Integration
of these data with pharmacokinetic (PK) data for GSK2126458
from oncology trials enabled modelling of an optimal dosing
regimen for IPF and the progression of GSK2126458 to an IPF
proof-of-mechanism (PoM) study (https://clinicaltrials.gov/ct2/
show/NCT01725139). As well as providing a rationale for pro-
gressing a novel therapeutic agent in IPF, these studies further
provide a new paradigm for the future re-positioning of existing
drugs as novel anti-ﬁbrotic agents.
METHODS
Patient material
All human samples were obtained with informed signed consent
and with research ethics committee approval (10/H0504/9, 10/
H0720/12 and 12/EM/0058). Patients with IPF were diagnosed
in accordance with current international guidelines.22 Tissue for
lung slice experiments was obtained from Asterand Europe
(Royston, UK) in compliance with the UK Human Tissue Act
2004.
Primary ﬁbroblast and bronchial epithelial cell culture
Primary human lung ﬁbroblasts (LFs) were grown from explant
cultures of IPF (IPF-LF) or non-IPF control (C-LF) lung tissue,
and cultured as previously described.23 Primary human bronchial
epithelial cells (HBECs) were isolated from regions of normal
airway from IPF or non-IPF control lung tissue as previously
described.24 See online supplementary material.
Immunohistochemistry
Immunostaining for pAktS473, pAktT308, αSMA and CD68 was
conducted on 4 μm formalin-ﬁxed parafﬁn-embedded serial sec-
tions of human lung biopsy material from n=12 patients with
IPF, using the avidin–biotinylated HRP enzyme complex method
(Vector Laboratories). Confocal dual-immunoﬂuorescence
microscopy for these markers was also performed on represen-
tative ﬁbrotic foci. See online supplementary material.
Akt phosphorylation and collagen synthesis in precision-cut
lung slices
Precision cut slices of IPF lung, 8 mm, were cultured for 24 h
in DMEM supplemented with 0.4% FCS (5% CO2/100%
humidity) prior to incubation with the PI3K inhibitors
Compound 1 or GSK2126458. The effect of short-term expos-
ure (2 h) to Compound 1 on Akt phosphorylation was assessed
by Milliplex Map (Millipore) bead assay of lung slice homoge-
nates prepared in ice cold PhosphoSafe buffer (Millipore). In
separate experiments, the effect of GSK2126458 on levels of
the collagen formation marker P1NP in tissue supernatant was
assessed by proprietary competitive ELISA (Nordic Bioscience)
as previously described.25 Slices were incubated with inhibitor
for up to 5 days prior to harvest. See online supplementary
material.
Fibroblast and BALF ﬂuid cell phospho-proteins
The effect of GSK2126458 on FCS-induced Akt phosphoryl-
ation in C-LFs (n=2) and IPF-LFs (n=5) was assessed by Meso
Scale Discovery (MSD) system. Phosphorylation events (pAkt
and pSMAD2) in C-LFs were also assessed by Western blot.
Densitometric analysis of Western blots was performed using
ImageQuant TL v8.1 software (GE Healthcare). The intensity of
bands in phospho-protein blots was divided by the intensity of
the total protein following stripping and re-probing. Values were
expressed as a ratio of the positive (stimulated) control. The
effect of GSK2126458 on bronchoalveolar lavage ﬂuid (BALF)
cell pellet obtained from patients with IPF (n=6) undergoing
routine diagnostic BAL was also assessed by MSD. See online
supplementary material.
Fibroblast proliferation
The effect of GSK2126458 on FCS-induced proliferation in
control (n=2) and IPF-derived primary human LFs (n=5) was
assessed by MTS assay. Fibroblast proliferation was also assessed
by 5-ethynyl-20deoxyuridine (EdU) incorporation into DNA of
primary human LFs (n=5 control, n=2 IPF). Fibroblast and
HBEC apoptosis was assessed by caspase 3,7 activation. See
online supplementary material.
Determination of collagen 1 gene expression and
Pro-collagen synthesis
Col1A1 gene expression in conﬂuent ﬁbroblast monolayers fol-
lowing TGFβ stimulation was assessed by RT-PCR following
TRIzol extraction as per the manufacturer’s instructions
(Thermo Fisher). RNA was DNAse treated using a DNAfree kit
(Ambion) and real-time RT-PCR conducted using the MESA
GREEN qPCR MasterMix Plus for SYBR Assay (Eurogentec).
Detailed methods are provided in the online supplementary
material. Fibroblast pro-collagen production was assessed by
high-performance liquid chromatography (HPLC) quantitation
of hydroxyproline in supernatants from conﬂuent ﬁbroblast
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monolayers, as previously described.26 Collagen biosynthesis
and deposition was also assessed by molecular crowding assay
modiﬁed from previously described methods using the IN Cell
Analyzer 6000 high content imaging system (GE Healthcare
Life Sciences).27 See online supplementary material.
RESULTS
Active PI3K signalling within IPF ﬁbrotic foci
We ﬁrst performed DAB-based immunohistochemistry (IHC) to
explore evidence of functional PI3K signalling in areas of active
ﬁbrosis in IPF lung biopsy material (representative sections from
Figure 1 Akt phosphorylation
co-localised within ﬁbrotic foci,
macrophages and bronchial epithelium
in the idiopathic pulmonary ﬁbrosis
(IPF) lung. Immunoﬂuorescence for α
smooth muscle actin (αSMA, green,
A and D), Akt phosphorylated at serine
473 (pAktS473, red, B) and threonine
308 (pAktT308, red, E) is shown
co-localised (C and F) within ﬁbrotic
foci (A–F). Immunoﬂuorescence for
CD68 (green, G and J), pAktS473
(red, H), pAktT308 (red, K) is shown
co-localised (I and L) within
macrophages in airspaces (panels
G–L). In panels M–R
immunoﬂuorescence for pAktS473 (red,
N), pAktT308 (red, Q) is shown localised
to unstained cells morphologically
characteristic of bronchial epithelium
(N, Q, O and R). Cells morphologically
characteristic of airway smooth muscle
are evident (green, M and P).
DAPI-stained nuclei are highlighted in
blue. 25 μm scale bars are shown.
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n=12 patients shown), assessing the phosphorylation state of the
critical downstream kinase, Akt. Online supplementary ﬁgure S1
shows prominent immunoreactivity for phosphorylated AktS473
and AktT308 localised to classic spindle-shaped, αSMA+ myoﬁ-
broblasts and epithelium overlying ﬁbrotic foci and cells mor-
phologically characteristic of capillary endothelium (see online
supplementary ﬁgure S1A,C,E). CD68+ macrophages residing in
airspaces also exhibited signals for pAktS473 and pAktT308 (see
online supplementary ﬁgure S1A,C,G). In contrast to myoﬁbro-
blasts in ﬁbrotic foci, airway smooth muscle cells demarcated by
αSMA+ signal showed little evidence of Akt phosphorylation,
while prominent phosphorylation was observed in the bronchial
epithelium (see online supplementary ﬁgure S1B,D,F). A more
detailed assessment of the cellular localisation of pAkt was pro-
vided by confocal dual immunoﬂuorescence (ﬁgure 1). These
studies conﬁrmed the localisation of both pAktS473 and pAktT308
to αSMA+ myoﬁbroblast subsets, however a differential staining
pattern was observed in the overlying epithelium which preferen-
tially exhibited signal for pAktS473 (ﬁgure 1A–F). In the bron-
chial epithelium, pAktS473 and pAktT308 showed differential
subcellular distribution, with pAktS473 distributed apically to
basolaterally throughout the cell layer, in comparison to
pAktT308 which was predominantly apically located (ﬁgure 1M–
R). αSMA+ airway smooth muscle was negative for pAkt. CD68
+ macrophages exhibited clear but heterogeneous staining
pattern for pAktS473 and pAktT308 (ﬁgure 1G–L).
Studies performed in live cultured precision-cut lung slices
obtained from a patient with IPF conﬁrmed prominent Akt phos-
phorylation in lung tissue and this signal was reduced in a
concentration-dependent manner following incubation with a
closely related analogue of GSK2126458, Compound 1 (ﬁgure 2)
(see online supplementary ﬁgure S2 for compound structures and
online supplementary table S1 for compound afﬁnity data).
GSK2126458 attenuates mitogenic responses in primary
human LFs in vitro
We next assessed the effect of GSK2126458 on Akt phosphoryl-
ation and proliferation of primary IPF and non-IPF control LFs
(IPF-LF and C-LF). GSK2126458 inhibited serum-induced pAkt
in C-LF (ﬁgure 3A and online supplementary table S2, geomet-
ric mean IC50=0.84 nM (range 0.43–1.64), n=2 donors) and
IPF-LF (ﬁgure 3C and online supplementary table S2, geometric
mean IC50=1.52 nM (95% CI 0.73 to 3.18), n=5 donors) in
IPF-LF. Figure 3E shows a representative Western blot illustrating
the effect of GSK2126458 on pAktS473 phosphorylation.
Figure 3B, D and online supplementary table S3 illustrate that
GSK2126458 also inhibited FCS-induced ﬁbroblast proliferation
(C-LF geometric mean IC50=18.70 nM (95% CI 12.45 to
28.08, n=2 donors), IPF-LF geometric mean=23.64 nM (95%
CI 13.61 to 41.07), n=5 donors) assessed by MTS assay. The
inhibitory effects of GSK2126458 on FCS-induced ﬁbroblast
proliferation were conﬁrmed using a second assay based on the
incorporation of the modiﬁed thymidine analogue, EdU, into
newly synthesised DNA (Click-iT EdU). The IC50 for
GSK2126458 obtained in this assay system was comparable to
that obtained in the MTS assay (ﬁgure 3F and online supplemen-
tary table S4, geometric mean IC50=15.91 nM; (95% CI 8.22
to 30.87)). Investigation of the effect of GSK2126458 on ﬁbro-
blast apoptosis (induction of caspase 3,7 activity), showed that
apoptosis was not detectable until concentrations ≥3 μM (ﬁgure
3G), indicating an approximately 25-fold window between the
potent anti-proliferative effects of GSK2126458 and the induc-
tion of apoptosis in LFs.
GSK2126458 inhibits Akt phosphorylation in IPF BALF cells
IHC studies (ﬁgure 1 and online supplementary ﬁgure S1)
revealed that macrophages within IPF alveolar spaces were
highly immunoreactive for pAkt. We therefore reasoned that
since macrophages are a prominent cell type in IPF BALF, this
observation could be exploited to develop a PD biosensor to
monitor in vivo inhibition of PI3K signalling by GSK2126458.
BALF differential cell counts conﬁrmed that macrophages
formed a prominent cell type (n=6, see online supplementary
table S5). Akt phosphorylation was observed for BALF cells
obtained for all patients and, incubation with GSK2126458
resulted in a concentration-dependent reduction in pAkt levels
(ﬁgure 4 and see online supplementary table S6, geometric
mean IC50=0.58 nM (95% CI 0.40 to 0.86)). The inhibitory
proﬁle of GSK2126458 was further found to be maintained in
BALF cells re-suspended in ice-cold saline for up to 35 min fol-
lowing incubation with the drug (data not shown).
Integrated PK/PD models to guide dose selection of
GSK2126458 in patients with IPF
To develop a dose rationale for GSK2126458 for future IPF
clinical trials, the data from these in vitro studies were integrated
with human PK data for GSK2126458 from ongoing clinical
trials in patients with advanced solid tumours (http://www.
gsk-clinicalstudyregister.com/study/112826#rs), according to
the scheme outlined in ﬁgure 5. Stochastic model simulations
were undertaken, providing predictions for pharmacological
engagement over time for a range of doses. According to the
model, the maximum tolerated dose of 2.5 mg twice a day
dosing, GSK2126458 would likely provide enough exposure to
signiﬁcantly impact on the key PD endpoints, including Akt
Figure 2 Pan-PI3 kinase (PI3K) dual mammalian target of rapamycin
(mTOR) inhibition reduces Akt phosphorylation in human idiopathic
pulmonary ﬁbrosis (IPF) lung slices. Precision cut lung slices were
treated with vehicle or increasing concentrations of PI3K inhibitor
(Compound 1) for 2 h (0.1% DMSO vehicle was constant for all
experimental conditions). Following harvest and homogenisation, pAkt
levels were assessed by Milliplex Map transforming growth factor
(TGF)-β signalling beads and normalised to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH). Data are shown for mean ﬂuorescence
intensity (MFI) normalised to GAPDH as ±SEM of n=4 technical
replicate wells per condition; *p<0.05, **p<0.01 (one-way ANOVA
with Tukey post-hoc testing).
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Figure 3 GSK2126458 inhibits Akt phosphorylation and proliferation in normal and idiopathic pulmonary ﬁbrosis (IPF) primary human lung
ﬁbroblasts. Control (C-LF, n=2, A) or IPF lung ﬁbroblasts (IPF-LF, n=5, C) were pre-incubated with increasing concentrations of GSK2126458.
Following 30 min stimulation with 20% FCS, pAktS473 signal was normalised to total Akt and expressed as % maximum response (maximum
asymptote) and is shown as mean±SEM of n=3 replicate wells per condition. A representative Western blot is shown visualising the effect of
GSK2126458 on FCS-induced phosphorylation of AktS473 in a representative C-LF line (E). Subconﬂuent control (C-LF, n=2, B) or IPF lung ﬁbroblasts
(IPF-LF, n=5, D) were pre-incubated with increasing concentrations of GSK2126458. Following 72 h stimulation with 10% FCS, ﬁbroblast
proliferation was measured using an MTS assay at 490 nm. Data were expressed as % maximum response (maximum asymptote) and are shown as
mean±n=6 replicate wells per condition. Incorporation of EdU (5-ethynyl-20deoxyuridine) into the DNA of sub-conﬂuent ﬁbroblasts was also used as
a measured of proliferation following 72 h of FCS stimulation (C-LF, n=5, dashed lines; IPF-LF, n=2, solid lines (F)). IC50 values (panels A–D and F)
were calculated using four-parameter non-linear regression, and representative curves are shown for each ﬁbroblast line. FCS stimulated and
unstimulated DMSO vehicle control ﬁbroblast data points are indicated as (+) and (−), respectively (panels A–F). DMSO was maintained at 0.1% for
all conditions. Activation of ﬁbroblast caspase 3 and 7 was assessed following incubation with increasing concentrations of GSK2126458 in the
presence of 10% FCS by Caspase Glo (G). FCS-stimulated (+) vehicle control (0.1% DMSO) ﬁbroblasts are indicated. Data are expressed as fold
relative to baseline cells (no FCS, 0.1% DMSO) and shown as mean±SEM of n=3 replicate wells per condition. **p<0.0001 for differences in raw
data values from FCS-stimulated controls (two-way ANOVA, Tukey’s multiple comparisons test).
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phosphorylation and ﬁbroblast proliferation in the lungs of
patients with IPF (table 1).
Effect of GSK2126458 on epithelial cell apoptosis
The observation that the epithelium also displays a prominent
pAkt signal lead us to further investigate the potential effect of
GSK2126458 on epithelial cell apoptosis. Figure 6 illustrates
that caspase 3,7 activity was induced in primary HBECs at con-
centrations of ≥3 μM (n=2 control donors, n=1 IPF donor).
GSK2126458 inhibits pro-ﬁbrotic responses to TGFβ1 in
primary human LFs in vitro
Progressive, excessive and disorganised deposition of collagen
and other extracellular matrix (ECM) proteins underlies the
gross remodelling leading to loss of lung function in IPF, with
TGFβ1 implicated as a critical mediator of this process.
5
Recent reports have further suggested the involvement of the
PI3K signalling axis in SMAD-independent TGFβ1 signal-
ling.15 28 We therefore also explored the potential of
GSK2126458 to interfere with TGFβ1-induced ﬁbroblast colla-
gen production.
We ﬁrst deﬁned the kinetics of PI3K activation in relation to
canonical SMAD signalling following TGFβ1 (1 ng/ml) stimula-
tion. Figure 7A, B illustrates that exogenous TGFβ1 induces
rapid phosphorylation of SMAD2 peaking at 2 h, with pAktS473
exhibiting a slower kinetic peaking at 12–24 h (ﬁgure 7D).
Delayed Akt phosphorylation is in agreement with previous
reports, suggesting the potential involvement of an autocrine
mediator.15 Of note in our experiments, this peak precedes the
peak of collagen (COL1A1) gene expression (36 h; ﬁgure 7C).
Figure 4 GSK2126458 inhibits Akt phosphorylation in
bronchoalveolar lavage (BALF) cells from patients with idiopathic
pulmonary ﬁbrosis (IPF). IPF BALF cells (n=6) were incubated with
0.1% DMSO (vehicle control) or increasing concentrations of
GSK2126458 for 30 min at 37°C (0.1% DMSO vehicle was constant for
all experimental conditions). Cell lysates were assayed for total Akt and
pAktS473 using Meso Scale Discovery (MSD) electro-chemiluminescence
technology. pAktS473 signal was normalised to total Akt signal and
expressed as % of a reference vehicle control well for each experiment
(Veh). Data are shown as mean±SEM of triplicate wells per condition.
IC50 values were calculated using four-parameter non-linear regression.
Figure 5 Construction of an
integrated pharmacokinetic (PK)/
pharmacodynamics (PD) model for
GSK2126458 in patients with
idiopathic pulmonary ﬁbrosis (IPF).
Schematic illustrating the strategy for
integration of in vitro PK/PD data with
human PK for clinical dose response
estimation in IPF. Equation (1): Inh
represents the % inhibition of pAkt
(IPF myoﬁbroblasts or bronchoalveolar
lavage ﬂuid (BALF) cell isolates) of
ﬁbroblast proliferation (IPF
myoﬁbroblasts), EMAX=maximum
estimated inhibition, EC50=drug
potency and shape=gradient of the
response curve. ε refers to residual or
unexplained variability, the subscript i
indicates replicate cell line, j is
individual drug concentration from
each cell line.
Table 1 Predicted pharmacodynamics of GSK2126458 in
idiopathic pulmonary fibrosis patients by dose (Max: maximum
inhibition (%), Min: minimum inhibition (%))
Dose (mg),
twice daily
pAkt/Akt Proliferation BAL
Max Min Max Min Max Min
0.25 14.3 8.3 24.5 19.2 24.2 12.4
1 35.8 23.2 36.4 30.4 62.5 45.7
2 49.6 34.9 42.5 37.1 76 65.2
2.5 54.1 38.7 44.6 39.6 79 69.7
BAL, bronchoalveolar lavage.
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We next assessed the effect of GSK2126458 on SMAD2 and
Akt phosphorylation at 12 h after the addition of exogenous
TGFβ1. Figure 7E shows that GSK2126458 had no inﬂuence on
SMAD2 phosphorylation but inhibited TGFβ1-induced Akt
phosphorylation in a concentration-dependent manner, with
maximum inhibition obtained at 10 nM (ﬁgure 7E,F).
We next characterised the potency of GSK2126458 for inhi-
biting TGFβ1 induced collagen deposition in myoﬁbroblasts,
using a novel high-content imaging based molecular crowding
assay.27 Figure 8A illustrates that GSK2126458 attenuated
TGFβ1-induced collagen deposition in ﬁbroblasts, with an IC50
of 132.5 nM (95% CI 65.5 to 268), and leads to a reduction in
cell number with an IC50 of 1.66 μM (95% CI 0.51 to 5.43).
Induction of caspase 3,7 in molecular crowded conditions is
consistent with concentrations of GSK2126458 which cause
reduction in cell count, suggesting apoptosis in crowded condi-
tions may be responsible for the observed reduction in cell
number (see online supplementary ﬁgure S3). Collectively these
data indicate a marked separation between the inhibitory effects
of GSK2126458 on collagen deposition and induction of apop-
tosis. For comparison, the selective TGFβRI (ALK5) inhibitor,
SB525334, inhibited TGFβ1 induced collagen deposition with
an IC50 of 200.5 nM (95% CI 159 to 252; ﬁgure 8B). Images
capturing the effects of inhibitors on primary ﬁbroblasts iso-
lated from IPF and control lungs in this assay are also shown
(ﬁgure 8C).
Pan-PI3K/mTOR inhibition reduces collagen formation
markers in ex vivo slices of IPF lung tissue
Our ﬁnal aim was to explore evidence for a direct functional
link between PI3K/mTOR signalling and matrix formation in
this disease setting by monitoring the release of the human pro-
collagen 1 amino-terminal peptide (P1NP) in IPF tissue slices
using a competitive ELISA based on a proprietary monoclonal
antibody.25 Figure 8D shows that the related GSK2126458 ana-
logue, Compound 1, reduced P1NP levels released into lung
slice supernatants, with maximal inhibition observed at
>100 nM; the effect of a Alk5 inhibitor, SB525334 (10 mM), is
also shown.
DISCUSSION
PI3K represents a key oncogenic signalling node, implicated in
a range of cellular processes from inﬂammation to cancer.
More recent evidence also suggests a role for this pathway in
ﬁbrosis, however to the best of our knowledge there are
currently no PI3K agents in clinical development for IPF or any
other ﬁbrotic condition. The aim of the current study was to
further explore the rationale for targeting PI3K signalling in
IPF and to deﬁne the pharmacological proﬁle of a potent and
clinically advanced PI3K/mTOR inhibitor, GSK2126458, as a
novel anti-ﬁbrotic.
PI3K mediates the conversion of phosphatidylinositol 4,5
bisphosphate (PIP2) to phosphatidylinositol 3,4,5 trisphosphate
(PIP3) at the plasma membrane, inducing the recruitment and
phosphorylation of Akt at threonine 308 (pAktT308) and serine
473 (pAktS473) to initiate downstream signalling. The initial
focus for our PI3K pathway validation studies in IPF was there-
fore to perform detailed IHC studies to determine Akt phos-
phorylation in IPF biopsy tissue. These studies showed
demonstrable immunoreactivity for pAktS473 associated with
activated myoﬁbroblasts within IPF ﬁbrotic foci, as previously
suggested.18 We further provide evidence for pAktT308 immu-
nostaining associated with these myoﬁbroblasts and thus provide
the ﬁrst evidence of full Akt activation in situ in this disease
context. Immunoﬂuorescent confocal co-localisation studies
further provide the ﬁrst evidence of cell-speciﬁc differential
phosphorylation of Akt: whereas pAktT308 immunostaining pre-
dominates in myoﬁbroblasts and a thin band of cells located at
the epithelial–mesenchymal border of ﬁbrotic foci, pAktS473
immunostaining was evident in both the epithelium and myoﬁ-
broblasts. Moreover, heterogeneous distribution and phosphor-
ylation of Akt were observed in bronchial epithelium and
macrophages in the IPF lung. Differential phosphorylation of
Akt has not been extensively studied; however in cancer, it has
been proposed to inﬂuence the interactions of Akt with its sub-
strates and thereby inﬂuence cell motility and invasion.29 30 Of
interest, in non-small cell lung cancer, elevated pAktT308 relative
to pAktS473 is associated with poor prognosis.31 Future studies
to determine the implications of differential phosphorylation of
Akt in the context of IPF are beyond the scope of this article
but may shed important light on the role of Akt in this disease
setting. Conﬁdence in PI3K as a target pathway was further
extended by functional studies in IPF-derived lung tissue. Akt
phosphorylation was readily detectable in precision-cut cultured
IPF lung slices and this signal was inhibited by pan-PI3K/dual
mTOR inhibition in a concentration-dependent manner.
Subsequent proliferation studies revealed that GSK2126458
inhibited serum-induced Akt phosphorylation and proliferation
at nanomolar potency with no difference in compound potency
observed. Of note, this anti-proliferative proﬁle of GSK2126458
is comparable to that observed in previous in vitro oncology
studies using the BT474 and T47D breast cancer lines.21
While pan-PI3K/mTOR inhibitors offer the advantage of
overcoming functional redundancy between class I isoforms,32
and blocking potential crosstalk and feedback of compensatory
mechanisms through inhibition of three key nodes (PI3K,
mTORC1 and mTORC2), the prospect for mechanism-based
on-target toxicities for this class of inhibitor, in particular with
respect to inducing apoptosis, are well documented.33 In our
studies, using primary LFs and bronchial epithelial cells, the
anticipated pro-apoptotic effects associated with inhibiting
Figure 6 Effect of GSK2126458 on epithelial cell apoptosis.
Activation of epithelial caspase 3 and 7 was assessed in primary
bronchial epithelial cultures following incubation with increasing
concentrations of GSK2126458 for 72 h (0.1% DMSO vehicle was
constant for all experimental conditions). Human bronchial epithelial
cell (HBEC) cultures were derived from n=2 control and n=1 idiopathic
pulmonary ﬁbrosis (IPF) donor lungs. Data are expressed fold relative to
baseline (0.1% DMSO) controls (Veh) and shown as mean±SEM of n=6
replicate wells per condition; **p<0.0001 for differences in raw data
values from no vehicle controls (two-way ANOVA, Tukey’s multiple
comparisons test).
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PI3K/mTOR signalling were not manifest until concentrations
of GSK2126458 were signiﬁcantly higher than those required
for exerting demonstrable anti-ﬁbroproliferative and
pro-apoptotic effects. This window is encouraging and suggests
there is considerable potential for GSK2126458 to be adminis-
tered at concentrations that would primarily impact on deleteri-
ous ﬁbroblast functional responses in IPF.
Assessment of drug PDs in the lung of patients with IPF is
challenging due to limitations associated with tissue access. Our
IHC observation of pAkt immunostaining being associated with
macrophages within airspaces raised the possibility that cells har-
vested from IPF BALF could serve as a potential PD biosensor
for monitoring effective pharmacological engagement of mech-
anism; namely, pAkt inhibition in the lungs of patients recruited
to early PoM studies. To this end, a BALF cell processing
protocol was developed which involved minimal cell handling
by assaying pAktS473 in whole BALF cell pellets on the basis that
macrophages were a prominent cell type present. These data
would also provide additional evidence from primary patient-
derived lung cells to further support a dose rationale for
GSK2126458. Interestingly, BALF cell pellets from patients with
IPF exhibited pAktS473 activation without the need for exogen-
ous stimulation and were sensitive to GSK2126458 inhibition, at
sub-nanomolar concentrations. Although inhibiting macrophage
function was not the major basis for exploring GSK2126458 as
a potential novel treatment for IPF, a potential role for macro-
phages, speciﬁcally alternatively activated M2 macrophages, is
becoming increasingly recognised.34–36 Recent studies have
implicated PI3K signalling in promoting M2 polarisation in
IPF-derived BAL macrophages,37 raising the possibility that
Figure 7 Time course of the primary
human ﬁbroblast response to
transforming growth factor (TGF)-β1.
Conﬂuent lung ﬁbroblasts (LFs) were
stimulated with TGFβ1 (1 ng/mL) and
lysates collected over the indicated
timecourse (A, B and D).
Phosphorylation of SMAD2 or AktS473
is shown by Western blot (A) and
densitometry (B and D). Collagen gene
expression in TGFβ1 (1 ng/mL)
stimulated (C, dark triangles and
dashed line) or unstimulated (C, light
triangles and dashed line) was
assessed in LFs over the indicated time
course. Pro-collagen recovered from
cell supernatants over the same time
course in TGFβ1 stimulated (C, dark
bar) or unstimulated (C, light bar) is
also shown. Serum-free conﬂuent
primary human LFs (HLFs) were
incubated with increasing
concentrations of GSK2126458 or
0.1% DMSO and stimulated with
TGFβ1 (1 ng/mL) for 12 h (0.1% DMSO
vehicle was constant for all
experimental conditions).
Phosphorylation of SMAD2 and AktS473
is shown by representative Western
blot (E). Densitometry illustrating the
effects of GSK2126458 on pAktS473 in
HLFs from n=3 donors is shown (F).
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modulating macrophage biology might itself provide an add-
itional beneﬁt to GSK2126458 treatment in this disease context.
To build a model for dose prediction in IPF, pharmacological
data obtained from ﬁbroblast signalling and mitogenic assays
were integrated with BALF cell PI3K phosphorylation data and
existing PK data from previous human oncology trials. The
model simulations predicted that within the typical clinical dose
range (2–3 mg twice daily), GSK2126458 would signiﬁcantly
impact ﬁbroblast PI3K signalling and proliferation in the lungs
of patients with IPF.
The decision to progress GSK2126458 to a PoM trial in IPF
was predicated on an appropriate dose rationale for this com-
pound as a ﬁbroblast anti-proliferative agent, based on the wide-
spread evidence linking this pathway to cell growth and
proliferative responses in multiple cell types and disease set-
tings.38 However, in terms of key IPF pathomechanisms, we
Figure 8 Pan-PI3 kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibition attenuates transforming growth factor (TGF)-β1-induced collagen
production in human lung ﬁbroblasts (LFs), and collagen formation markers in idiopathic pulmonary ﬁbrosis (IPF) lung tissue. Conﬂuent LFs were
incubated with increasing concentrations of GSK2126458 (A) or SB525334 (B) and stimulated for 48 h with TGFβ1 (1 ng/mL) and collagen
biosynthesis assayed by molecular crowding assay (0.1% DMSO vehicle was constant for all experimental conditions). Data are expressed as mean
ﬂuorescent intensity (n=4 reads per well) and cell counts obtained from DAPI counterstaining (blue channel). Data are shown as mean±SEM of n=3
replicate wells per condition. IC50 values were calculated using four-parameter non-linear regression. Replicate experiments were carried out on
human lung ﬁbroblasts (HLFs) from a non-IPF donor and representative curves are shown. Images from each cell treatment are shown (C). 8 mm
slices of IPF lung were cultured for 24 h in DMEM supplemented with 0.4% FCS and treated with vehicle, 10 μM SB525334 (open circles) or
increasing concentrations of Compound 1 (inhibitor) for 0–3 days (ﬁlled grey circles) and further from 3 to 5 days (ﬁlled black circles) following
media change. P1NP levels were measured in harvested supernatants (D). Data are shown as ±SEM of n=4 replicate wells per condition; *p<0.05,
**p<0.01 (two-way ANOVA with Bonferroni post-hoc testing).
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were also interested in determining the potential of this agent to
inhibit TGFβ1-induced myoﬁbroblast collagen production, based
on limited literature reports suggesting the involvement of PI3K
in SMAD-independent TGFβ1 signalling.
15 28 These studies
revealed that GSK2126458 was highly effective at attenuating
TGFβ1-induced myoﬁbroblast collagen deposition at concentra-
tions around the 100 nM range.
Our ﬁnal aim was to directly link PI3K/mTOR signalling to
pro-ﬁbrotic collagen formation in IPF lung tissue using an ex
vivo human tissue model. Type I collagen is the most repre-
sented extracellular protein in the lungs and its dysregulated
turnover is a hallmark of ﬁbrosis. During maturation of type I
collagen, soluble pro-collagen is processed to its insoluble form
by carboxy and amino terminal endopeptidase cleavage, generat-
ing peptide fragments such as the N-terminal P1NP which can
be monitored as a sensitive biomarker of collagen formation.25
Our studies revealed that P1NP was released from ex-vivo IPF
precision-cut lung slices for up to 5 days in culture and further
that PI3K/mTOR inhibition attenuated this process. To the best
of our knowledge, these studies represent the ﬁrst direct demon-
stration of a direct functional link between PI3K/mTOR signal-
ling and ECM formation in this human disease setting. It is
noteworthy that in isolated ﬁbroblasts and in lung tissue slices,
the pan-PI3K/mTOR inhibitors exhibited comparable efﬁcacy
to the selective TGFβRI (Alk-5) inhibitor, SB525334. This raises
the possibility that GSK2126458 could interfere with the ﬁbro-
genic effects of TGFβ1 signalling at clinically attainable doses,
while potentially sparing its essential homeostatic and tumour
suppressor functions. This is a particularly important consider-
ation in patients with IPF who are at a heightened risk of devel-
oping lung cancer.5 39
In conclusion, we have considerably extended the scientiﬁc
rationale for targeting PI3K signalling in IPF using patient-
derived cells and lung tissue. We provide evidence for active
PI3K signalling in the ﬁbrotic foci of IPF patients together with
data that GSK2126458 attenuates serum-induced proliferation
and TGFβ1-induced collagen production in IPF ﬁbroblasts.
Population modelling and integration of preclinical biomarker
data with human PK data has enabled us to develop a dosing
framework which should safely and effectively engage PI3K sig-
nalling in the lungs of patients with IPF, providing support for
progressing GSK2126458 to further clinical evaluation in IPF in
a dose-ﬁnding, double-blind, placebo-controlled study (https://
clinicaltrials.gov/ct2/show/NCT01725139). To the best of our
knowledge, this represents the ﬁrst IPF clinical study aimed at
assessing target engagement and tolerability of a PI3K/mTOR
inhibitor in this disease setting.
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